RA0756

antibody from Oursmab

Targeting: TNFRSF12A CD266, FN14, TweakR

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0756

Provider

Oursmab

Product name

Enavatuzumab (Biosimilar Reference Antibody) (TNFRSF12A)

Antibody type

Monoclonal

Description

Enavatuzumab is an investigational, humanized immunoglobulin G1 (IgG1) monoclonal antibody developed for the treatment of advanced solid tumors. It functions as a targeted agent against the TWEAK receptor (TweakR) with a dual mechanism of action. First, upon binding to TweakR on the surface of tumor cells, it can induce direct anti-proliferative and pro-apoptotic signaling within the cancer cell itself. Second, leveraging its IgG1 Fc domain, it engages the immune system to eliminate tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This combined approach aims to inhibit tumor growth both by intrinsic signaling blockade and extrinsic immune-mediated killing.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.